Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Number of patients with poor prognosis and high levels of XCL1
研究概览
简要总结
The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
详细描述
Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with newly diagnosed acute lymphoblastic leukemia .
排除标准
- •Patients with prior treatment with chemotherapeutic agents.
- •Patients treated with immunosuppressants.
- •Patients under 12 months old.
- •Patients with a diagnosis or history of autoimmune diseases.
- •Patients with a diagnosis or history of immunosuppressive diseases.
- •Patients who do not agree to sign a Letter of Informed Consent.
结局指标
主要结局
Number of patients with poor prognosis and high levels of XCL1
时间窗: 3 months
Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
Number of patients with poor prognosis and high levels of cytokines
时间窗: 3 months
Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.
次要结局
未报告次要终点
研究者
David Gomez Almaguer
MD
Hospital Universitario Dr. Jose E. Gonzalez